ProShare Advisors LLC Purchases 5,517 Shares of Insulet Corporation $PODD

ProShare Advisors LLC grew its position in Insulet Corporation (NASDAQ:PODD) by 44.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 17,993 shares of the medical instruments supplier’s stock after acquiring an additional 5,517 shares during the period. ProShare Advisors LLC’s holdings in Insulet were worth $5,114,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. HighTower Advisors LLC lifted its stake in shares of Insulet by 211.4% in the 4th quarter. HighTower Advisors LLC now owns 7,921 shares of the medical instruments supplier’s stock valued at $2,251,000 after acquiring an additional 5,377 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in shares of Insulet in the 4th quarter valued at $269,000. North Dakota State Investment Board bought a new position in shares of Insulet in the 4th quarter valued at $683,000. Elyxium Wealth LLC bought a new position in shares of Insulet in the 4th quarter valued at $28,000. Finally, Abacus Wealth Partners LLC bought a new position in shares of Insulet in the 4th quarter valued at $225,000.

Insiders Place Their Bets

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the stock in a transaction dated Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.36% of the company’s stock.

Insulet Stock Down 1.3%

Shares of NASDAQ:PODD opened at $154.87 on Friday. The firm has a market cap of $10.73 billion, a P/E ratio of 36.02, a P/E/G ratio of 1.22 and a beta of 1.20. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12-month low of $145.59 and a 12-month high of $354.88. The business has a fifty day simple moving average of $191.53 and a 200 day simple moving average of $251.28.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period last year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts predict that Insulet Corporation will post 6.43 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Royal Bank Of Canada dropped their price target on Insulet from $325.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Leerink Partners dropped their price target on Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Citigroup lowered their target price on Insulet from $230.00 to $175.00 in a research report on Thursday, May 7th. Finally, Piper Sandler lowered their target price on Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $254.96.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.